RY 133.21 -0.0675% TD 78.64 0.4599% SHOP 95.75 0.136% CNR 174.55 -0.2172% ENB 46.51 1.3511% CP 115.18 -0.3375% BMO 125.12 -0.1197% TRI 207.83 -1.3153% CNQ 105.4 -0.8467% BN 52.885 -1.5544% ATD 75.13 -0.186% CSU 3670.4399 -1.1052% BNS 64.03 -0.2959% CM 64.91 0.1698% SU 52.315 0.2587% TRP 48.59 0.5796% NGT 53.03 -0.0942% WCN 226.63 -0.0838% MFC 31.51 0.2226% BCE 44.31 -0.2476%

GenixPharmaceucticals Corporation

Healthcare CA GENX

0.055CAD
-0.005(8.33%)

Last update at 2024-04-18T13:30:00Z

Day Range

0.060.06
LowHigh

52 Week Range

0.020.08
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-10-31 2021-10-31 2020-10-31 2019-10-31 2018-10-31
Type yearly yearly yearly yearly yearly
Date 2022-10-31 2021-10-31 2020-10-31 2019-10-31 2018-10-31
Income before tax -1.07400M -1.65252M -0.71866M -0.16470M -0.02484M
Minority interest - - - - -
Net income -1.07400M -1.65252M -0.71866M -0.16470M 0.13M
Selling general administrative 0.43M 1.12M 0.35M 0.10M 0.12M
Selling and marketing expenses - - - - -
Gross profit - - 0.00000M -0.04569M 0.09M
Reconciled depreciation 0.56M 0.54M 0.36M 0.00025M 0.00011M
Ebit -0.99843M -1.61037M -0.67879M -0.12320M -0.02405M
Ebitda -0.49769M -1.11240M -0.35321M -0.16267M -0.02391M
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income -1.03122M -1.65493M -0.71520M -0.14334M -0.02494M
Other operating expenses - - - - -
Interest expense 0.01M 0.00351M 0.00388M 0.00178M 0.00083M
Tax provision - - - - -
Interest income 0.00015M 0.00145M 0.00043M - 0.00000M
Net interest income -0.01199M -0.00206M -0.00345M -0.00178M -0.00083M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - - -
Total revenue 0.00000M 0.00000M 0.00000M 0.14M 0.42M
Total operating expenses 1.03M 1.65M 0.72M 0.28M 0.44M
Cost of revenue - - 0.00000M 0.18M 0.33M
Total other income expense net -0.03080M 0.00447M -0.00001M -0.01959M 0.00093M
Discontinued operations - - - - 0.16M
Net income from continuing ops -1.07400M -1.65252M -0.71866M -0.16470M -0.02520M
Net income applicable to common shares -1.07400M -1.65252M -0.71866M -0.16470M 0.13M
Preferred stock and other adjustments - - - - -
Breakdown 2022-10-31 2021-10-31 2020-10-31 2019-10-31 2018-10-31
Type yearly yearly yearly yearly yearly
Date 2022-10-31 2021-10-31 2020-10-31 2019-10-31 2018-10-31
Total assets 4.25M 4.77M 5.35M 0.04M 0.23M
Intangible assets 4.01M 4.55M 4.63M - -
Earning assets - - - - -
Other current assets - - - - 0.01M
Total liab 1.05M 0.76M 0.49M 0.08M 0.11M
Total stockholder equity 3.20M 4.01M 4.86M -0.04213M 0.12M
Deferred long term liab - - - - -
Other current liab 0.64M 0.66M 0.20M - -
Common stock 9.70M 9.70M 9.70M 4.19M 4.19M
Capital stock 9.70M 9.70M 9.70M 4.19M 4.19M
Retained earnings -7.73513M -6.66113M -5.00861M -4.28995M -4.12525M
Other liab - - 0.14M - -
Good will - - - - -
Other assets - - - - -
Cash 0.00927M 0.14M 0.70M 0.03M 0.07M
Cash and equivalents - - - - -
Total current liabilities 1.05M 0.74M 0.35M 0.08M 0.11M
Current deferred revenue - - - - -
Net debt 0.17M - - - -
Short term debt - - - 0.02M -
Short long term debt 0.18M 0.02M 0.21M 0.02M -
Short long term debt total - - - - -
Other stockholder equity 1.23M 0.97M 0.17M 0.06M 0.06M
Property plant equipment 0.00373M 0.03M - - 0.00025M
Total current assets 0.24M 0.19M 0.72M 0.04M 0.23M
Long term investments - - - - -
Net tangible assets -0.80947M -0.53456M 0.23M -0.04213M 0.12M
Short term investments - - - - -
Net receivables 0.02M 0.00487M 0.00791M 0.00393M 0.12M
Long term debt - - 0.14M - -
Inventory 0.17M 0.00483M - 0.00000M 0.05M
Accounts payable 0.21M 0.01M 0.12M 0.05M 0.08M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - 0.00000M 0.00025M
Deferred long term asset charges - - - - -
Non current assets total 4.01M 4.58M 4.63M 0.00000M 0.00025M
Capital lease obligations 0.00488M 0.03M - - -
Long term debt total - - - - -
Breakdown 2022-10-31 2021-10-31 2020-10-31 2019-10-31 2018-10-31
Type yearly yearly yearly yearly yearly
Date 2022-10-31 2021-10-31 2020-10-31 2019-10-31 2018-10-31
Investments -0.00334M - -0.00800M 0.00000M -0.06534M
Change to liabilities 0.18M -0.09352M 0.08M -0.04260M 0.04M
Total cashflows from investing activities -0.00334M -0.00334M -0.00800M -0.00800M -0.06534M
Net borrowings 0.15M -0.01400M -0.00540M 0.02M 0.02M
Total cash from financing activities 0.09M -0.12948M 0.87M 0.02M 0.02M
Change to operating activities -0.00354M -0.02844M -0.00625M -0.00972M -0.01119M
Net income -1.07400M -1.65252M -0.71866M -0.16470M 0.13M
Change in cash -0.12955M -0.55779M 0.67M -0.03855M -0.03116M
Begin period cash flow 0.14M 0.70M 0.03M 0.07M 0.10M
End period cash flow 0.00927M 0.14M 0.70M 0.03M 0.07M
Total cash from operating activities -0.21958M -0.42831M -0.19503M -0.05855M 0.03M
Issuance of capital stock - - 1.01M - -
Depreciation 0.56M 0.54M 0.36M 0.00025M 0.00011M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory -0.16649M -0.00483M -0.00483M 0.05M 0.05M
Change to account receivables -0.01163M 0.00304M -0.00398M 0.11M -0.04899M
Sale purchase of stock - - - - -
Other cashflows from financing activities -0.05499M -0.11548M -0.13279M -0.13279M -0.13279M
Change to netincome 0.30M 0.81M 0.10M 0.00058M -0.13188M
Capital expenditures 0.00334M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.00567M -0.12376M 0.07M 0.04M 0.03M
Stock based compensation 0.26M 0.81M 0.10M - -
Other non cash items 0.00861M 0.00198M - 0.07M -
Free cash flow -0.22292M -0.42831M -0.19503M -0.05855M 0.03M

Fundamentals

  • Previous Close 0.06
  • Market Cap2.37M
  • Volume1000
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-0.27113M
  • Revenue TTM0.01M
  • Revenue Per Share TTM-
  • Gross Profit TTM -0.00471M
  • Diluted EPS TTM-0.02

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
GENX
GenixPharmaceucticals Corporation
-0.005 8.33% 0.06 - - 191.87 0.92 225.59 -9.3187
RX
Biosyent Inc.
-0.1 1.17% 8.45 16.47 16.26 3.21 2.88 2.32 8.03
LOVE
Cannara Biotech Inc
0.01 1.16% 0.87 10.00 - 1.26 0.90 1.98 7.20
DB
Decibel Cannabis Company Inc
-0.005 3.57% 0.14 - 3.38 0.48 1.17 0.87 39.48
LSL
LSL Pharma Group Inc.
- -% 0.41 - - 4.65 4.23 6.13 -14.2493

Reports Covered

Stock Research & News

Profile

Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with focus on nutraceuticals and pharmaceuticals in Canada. The company develops Flu-X, an anti-viral, anti-flu, and common colds coronavirus oral and spray herbal product; Renochlor, a dietary supplement to aid in the restoration of kidney health and kidney function; and Sucanon, an insulin sensitizer that manages blood sugar. It also markets and sells nutraceuticals and pharmaceutical products, such as bee propolis capsules, calcium liquid softgels, seal oil softgels, marine lipid softgels, Lecithin softgels, fish oil softgels, EPO softgels, and spirulina powder, as well as eye ointments and drops. The company was formerly known as Alta Natural Herbs & Supplements Ltd. and changed its name to Genix Pharmaceuticals Corporation in June 2019. Genix Pharmaceuticals Corporation was incorporated in 1993 and is based in Vancouver, Canada.

GenixPharmaceucticals Corporation

10022 ? 102 Avenue, Vancouver, BC, Canada, T8V 0Z7

Key Executives

Name Title Year Born
Mr. Sina Salehi Pirooz CEO & Director NA
Mr. Mahmoud S. Aziz Pres & Director 1958
Mr. Wayne Kent Lee CA, CPA Chief Financial Officer 1968
Mr. Kevin James Bottomley Director of Corp. Devel. & Independent Director NA
Dr. Haofang Song Mang. NA
Ms. Monita Franziska Valeska Faris Company Sec. 1967

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).